Agomab Therapeutics shares drop in Nasdaq debut with valuation at 716 million dollars
Shares of Belgian firm Agomab Therapeutics fell 8% in their Nasdaq debut on Friday. The company reached a valuation of roughly 716 million dollars.
Insights:
Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on February 6, 2026, valuing the Belgium 
BE-based company at $716.4 million. This immediate share decline determined the company's market valuation at listing and indicates the market reception to the debut.
BE-based company at $716.4 million. This immediate share decline determined the company's market valuation at listing and indicates the market reception to the debut.
